Compare McCormick & Company, Incorporated (MKC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? McCormick & Company, Incorporated trades at $51.43 (market cap $13.96B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: McCormick & Company, Incorporated pays a 3.7% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, McCormick & Company, Incorporated nearer its low. Which is the better fit depends on your goals.
| MKC | XBI | |
|---|---|---|
Market Cap | $13.96B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $71.65 | $169.55 |
52-Week Low | $45.60 | $93.43 |
Enterprise Value | $18.57B | — |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.64, net income margin of 21.91%, and consistent dividend growth. Recent Q1 2026 earnings beat expectations, while analyst consensus remains mixed with 11 buy, 17 hold, and 2 sell ratings. The pending $65 billion Unilever Foods merger and London listing plans represent significant corporate developments.
MKC presents a compelling value opportunity with attractive valuation metrics and stable profitability. The Unilever merger offers substantial growth potential but carries integration risks. Current technical weakness near support at $50-$51 creates a potential entry point for long-term investors seeking dividend income and merger upside.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
